364 related articles for article (PubMed ID: 16020742)
1. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.
Gardner OS; Dewar BJ; Graves LM
Mol Pharmacol; 2005 Oct; 68(4):933-41. PubMed ID: 16020742
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of PPARs: from molecular characterization to physiological relevance.
Diradourian C; Girard J; Pégorier JP
Biochimie; 2005 Jan; 87(1):33-8. PubMed ID: 15733734
[TBL] [Abstract][Full Text] [Related]
4. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
Gelman L; Michalik L; Desvergne B; Wahli W
Curr Opin Cell Biol; 2005 Apr; 17(2):216-22. PubMed ID: 15780600
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
6. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
7. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor.
Galandrin S; Oligny-Longpré G; Bonin H; Ogawa K; Galés C; Bouvier M
Mol Pharmacol; 2008 Jul; 74(1):162-72. PubMed ID: 18403719
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Giaginis C; Tsantili-Kakoulidou A; Theocharis S
Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
[TBL] [Abstract][Full Text] [Related]
9. Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells.
Takeda M; Otsuka F; Otani H; Inagaki K; Miyoshi T; Suzuki J; Mimura Y; Ogura T; Makino H
J Endocrinol; 2007 Jul; 194(1):87-99. PubMed ID: 17592024
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors and inflammation.
Moraes LA; Piqueras L; Bishop-Bailey D
Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
Smeets PJ; Planavila A; van der Vusse GJ; van Bilsen M
Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
14. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha.
Yoon MJ; Lee GY; Chung JJ; Ahn YH; Hong SH; Kim JB
Diabetes; 2006 Sep; 55(9):2562-70. PubMed ID: 16936205
[TBL] [Abstract][Full Text] [Related]
16. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation.
Gardner OS; Dewar BJ; Earp HS; Samet JM; Graves LM
J Biol Chem; 2003 Nov; 278(47):46261-9. PubMed ID: 12966092
[TBL] [Abstract][Full Text] [Related]
17. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
Collino M; Patel NS; Thiemermann C
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):179-97. PubMed ID: 19124421
[TBL] [Abstract][Full Text] [Related]
18. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
19. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
[TBL] [Abstract][Full Text] [Related]
20. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).
Peraza MA; Burdick AD; Marin HE; Gonzalez FJ; Peters JM
Toxicol Sci; 2006 Apr; 90(2):269-95. PubMed ID: 16322072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
